MedTrace Logo

Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy

NCT00681928 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2011-12-02

No results posted yet for this study

Summary

RATIONALE: Gathering information about cognitive function over time in postmenopausal women with breast cancer may help doctors learn about the long-term effects of aromatase inhibitor therapy and plan the best treatment.

PURPOSE: This clinical trial is studying cognitive function in older postmenopausal women with stage I, stage II, or stage III breast cancer receiving hormone therapy and in healthy volunteers.

Conditions

Interventions

DRUG

anastrozole

As determined by the subject's physician

DRUG

letrozole

As determined by the subject's physician

OTHER

questionnaire administration

For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.

PROCEDURE

cognitive assessment

For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.

PROCEDURE

psychosocial assessment and care

For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Arti Hurria, MD · City of Hope Comprehensive Cancer Center

Eligibility

Min Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00681928 on ClinicalTrials.gov